| Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes P Gæde, P Vedel, N Larsen, GVH Jensen, HH Parving, O Pedersen New England Journal of Medicine 348 (5), 383-393, 2003 | 5304 | 2003 |
| Effect of a multifactorial intervention on mortality in type 2 diabetes P Gæde, H Lund-Andersen, HH Parving, O Pedersen New England Journal of Medicine 358 (6), 580-591, 2008 | 3516 | 2008 |
| Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study P Gæde, P Vedel, HH Parving, O Pedersen The Lancet 353 (9153), 617-622, 1999 | 1147 | 1999 |
| Mutation analysis of peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus J Ek, G Andersen, SA Urhammer, PH Gaede, T Drivsholm, ... Diabetologia 44 (12), 2220-2226, 2001 | 355 | 2001 |
| Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial P Gæde, J Oellgaard, B Carstensen, P Rossing, H Lund-Andersen, ... Diabetologia 59 (11), 2298-2307, 2016 | 245 | 2016 |
| Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria P Gæde, L Tarnow, P Vedel, HH Parving, O Pedersen Nephrology Dialysis Transplantation 19 (11), 2784-2788, 2004 | 224 | 2004 |
| Double‐blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients P Gaede, HE Poulsen, HH Parving, O Pedersen Diabetic Medicine 18 (9), 756-760, 2001 | 155 | 2001 |
| Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study P Gæde, WJ Valentine, AJ Palmer, DMD Tucker, M Lammert, HH Parving, ... Diabetes Care 31 (8), 1510-1515, 2008 | 151 | 2008 |
| Intensive integrated therapy of type 2 diabetes: implications for long-term prognosis P Gæde, O Pedersen Diabetes 53 (suppl 3), S39-S47, 2004 | 135 | 2004 |
| Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy P Rossing, K Rossing, P Gæde, O Pedersen, HH Parving Diabetes care 29 (5), 1024-1030, 2006 | 127 | 2006 |
| Intensified multifactorial intervention and cardiovascular outcome in type 2 diabetes: the Steno-2 study O Pedersen, P Gæde Metabolism 52, 19-23, 2003 | 105 | 2003 |
| Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria P Gaede, P Hildebrandt, G Hess, HH Parving, O Pedersen Diabetologia 48 (1), 156-163, 2005 | 100 | 2005 |
| A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes S Maeda, M Kobayashi, S Araki, T Babazono, BI Freedman, MA Bostrom, ... PLoS genetics 6 (2), e1000842, 2010 | 93 | 2010 |
| The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes PH Gaede, PV Jepsen, JN Larsen, GV Jensen, HH Parving, OB Pedersen Ugeskrift for laeger 165 (26), 2658, 2003 | 63 | 2003 |
| Polymorphisms in the 3′ UTR in the neurocalcin δ gene affect mRNA stability, and confer susceptibility to diabetic nephropathy M Kamiyama, M Kobayashi, S Araki, A Iida, T Tsunoda, K Kawai, ... Human genetics 122 (3-4), 397-407, 2007 | 59 | 2007 |
| Limited impact of lifestyle education in patients with Type 2 diabetes mellitus and microalbuminuria: results from a randomized intervention study P Gaede, M Beck, P Vedel, O Pedersen Diabetic Medicine 18 (2), 104-108, 2001 | 54 | 2001 |
| Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits J Oellgaard, P Gæde, P Rossing, F Persson, HH Parving, O Pedersen Kidney international 91 (4), 982-988, 2017 | 32 | 2017 |
| Elevated levels of plasma von Willebrand factor and the risk of macro‐and microvascular disease in type 2 diabetic patients with microalbuminuria P Gæde, P Vedel, HH Parving, O Pedersen Nephrology Dialysis Transplantation 16 (10), 2028-2033, 2001 | 31 | 2001 |
| Impact of low‐dose acetylsalicylic acid on kidney function in type 2 diabetic patients with elevated urinary albumin excretion rate P Gæde, HP Hansen, HH Parving, O Pedersen Nephrology Dialysis Transplantation 18 (3), 539-542, 2003 | 29 | 2003 |
| Target intervention against multiple‐risk markers to reduce cardiovascular disease in patients with type 2 diabetes P Gaede, O Pedersen Annals of medicine 36 (5), 355-366, 2004 | 27 | 2004 |
